BEYOND SYMPTOM CONTROL: ADHD PHARMACOTHERAPY AND REAL-WORLD RISK REDUCTION – A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6564Keywords:
Attention-Deficit/Hyperactivity Disorder, ADHD Pharmacotherapy, Real-World Outcomes, Risk Reduction, Cardiovascular Safety, MortalityAbstract
Background: ADHD is associated with substantial impairment and elevated risks of severe real-world adverse events across the lifespan (e.g., suicidal behavior, motor vehicle crashes, substance misuse, criminality, and premature mortality). While randomized trials establish short-term efficacy for symptom control, evaluating long-term real-world risk reduction requires synthesizing evidence from diverse observational and causal-inference designs.
Aim: This narrative review synthesizes current evidence on the association between ADHD pharmacotherapy and major real-world functional outcomes, balancing behavioral risk reduction against potential long-term cardiovascular safety concerns.
Methodology: We searched PubMed, Web of Science, Embase, and PsycINFO for studies on stimulant and non-stimulant treatments. Evidence from randomized trials, register-based studies, within-individual comparisons, and target-trial emulations was synthesized narratively, focusing on how study design affects causal inference.
Results: ADHD pharmacotherapy is associated with lower rates of suicidal behavior, substance-related problems, transport accidents, criminal convictions, psychiatric hospitalizations, and premature mortality. Conversely, long-term cumulative exposure—particularly to stimulants—is linked to increasing cardiovascular risk, especially hypertension, with stronger associations at longer durations and higher doses.
Conclusions: ADHD pharmacotherapy contributes to critical real-world risk reduction beyond core symptom control. Clinical decisions should balance these behavioral and survival benefits against potential long-term cardiovascular risks through ongoing safety monitoring and individualized benefit-risk assessments.
References
Coghill, D. R., Banaschewski, T., Soutullo, C., Cottingham, M. G., & Zuddas, A. (2017). Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. European Child & Adolescent Psychiatry, 26(11), 1283–1307.
Kosheleff, A. R., Mason, O., Jain, R., Koch, J., & Rubin, J. (2023). Functional impairments associated with ADHD in adulthood and the impact of pharmacological treatment. Journal of Attention Disorders, 27(7), 669–697.
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738.
Elliott, J., Johnston, A., Husereau, D., Kelly, S. E., Eagles, C., Charach, A., Hsieh, S.-C., Bai, Z., Hossain, A., Skidmore, B., Tsakonas, E., Chojecki, D., Mamdani, M., & Wells, G. A. (2020). Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. PLOS ONE, 15(10), Article e0240584.
Boland, H., DiSalvo, M., Fried, R., Woodworth, K. Y., Wilens, T., Faraone, S. V., & Biederman, J. (2020). A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of Psychiatric Research, 123, 21–30.
Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D’Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860.
Li, L., Coghill, D., Sjölander, A., Yao, H., Zhang, L., Kuja-Halkola, R., Brikell, I., Lichtenstein, P., D’Onofrio, B. M., Larsson, H., & Chang, Z. (2025). Increased prescribing of attention-deficit/hyperactivity disorder medication and real-world outcomes over time. JAMA Psychiatry, 82(8), 830–837.
Zhang, L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M., Kuja-Halkola, R., Brikell, I., Lichtenstein, P., D’Onofrio, B. M., Larsson, H., Cortese, S., & Chang, Z. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: Emulation of target trials. BMJ, 390, Article e083658.
Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187.
Hernán, M. A., & Robins, J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 183(8), 758–764.
Chang, Z., Quinn, P. D., O’Reilly, L., Sjölander, A., Hur, K., Gibbons, R., Larsson, H., & D’Onofrio, B. M. (2020). Medication for attention-deficit/hyperactivity disorder and risk for suicide attempts. Biological Psychiatry, 88(6), 452–458.
Man, K. K. C., Coghill, D., Chan, E. W., Lau, W. C. Y., Hollis, C., Liddle, E., Banaschewski, T., McCarthy, S., Neubert, A., Sayal, K., Ip, P., Schuemie, M. J., Sturkenboom, M. C. J. M., Sonuga-Barke, E., Buitelaar, J., Carucci, S., Zuddas, A., Kovshoff, H., Garas, P., … Wong, I. C. K. (2017). Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry, 74(10), 1048–1055.
Pan, T.-L., Chen, L.-C., Hsu, J.-W., Bai, Y.-M., Tsai, S.-J., Chen, T.-J., & Chen, M.-H. (2026). Suicide attempt risk among patients receiving methylphenidate: A retrospective cohort study. Psychopharmacology. Advance online publication.
Adams, S. M., Meraz, R., O’Reilly, L. M., Riley, T., Froehlich, T., Chang, Z., Quinn, P. D., & D’Onofrio, B. M. (2026). Pharmacotherapies for attention-deficit/hyperactivity disorder and risk of suicidal behavior: A within-individual study of stimulants, atomoxetine, and alpha-2 agonists. Biological Psychiatry: Global Open Science, 6(3), Article 100698.
Chang, Z., Lichtenstein, P., Halldner, L., D’Onofrio, B., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2014). Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry, 55(8), 878–885.
Quinn, P. D., Chang, Z., Hur, K., Gibbons, R. D., Lahey, B. B., Rickert, M. E., Sjölander, A., Lichtenstein, P., Larsson, H., & D’Onofrio, B. M. (2017). ADHD medication and substance-related problems. American Journal of Psychiatry, 174(9), 877–885.
Konstenius, M., Jayaram-Lindström, N., Guterstam, J., Beck, O., Philips, B., & Franck, J. (2014). Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: A 24-week randomized placebo-controlled trial. Addiction, 109(3), 440–449.
Brunkhorst-Kanaan, N., Libutzki, B., Reif, A., Larsson, H., McNeill, R. V., & Kittel-Schneider, S. (2021). ADHD and accidents over the life span – A systematic review. Neuroscience & Biobehavioral Reviews, 125, 582–591.
Ruiz-Goikoetxea, M., Cortese, S., Aznarez-Sanado, M., Magallón, S., Alvarez Zallo, N., Luis, E. O., de Castro-Manglano, P., Soutullo, C., & Arrondo, G. (2018). Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 84, 63–71.
Man, K. K. C., Chan, E. W., Coghill, D., Douglas, I., Ip, P., Leung, L.-P., Tsui, M. S. H., Wong, W. H. S., & Wong, I. C. K. (2015). Methylphenidate and the risk of trauma. Pediatrics, 135(1), 40–48.
Ghirardi, L., Larsson, H., Chang, Z., Chen, Q., Quinn, P. D., Hur, K., Gibbons, R. D., & D’Onofrio, B. M. (2020). Attention-deficit/hyperactivity disorder medication and unintentional injuries in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 59(8), 944–951.
Aduen, P. A., Kofler, M. J., Sarver, D. E., Wells, E. L., Soto, E. F., & Cox, D. J. (2018). ADHD, depression, and motor vehicle crashes: A prospective cohort study of continuously-monitored, real-world driving. Journal of Psychiatric Research, 101, 42–49.
Chang, Z., Quinn, P. D., Hur, K., Gibbons, R. D., Sjölander, A., Larsson, H., & D’Onofrio, B. M. (2017). Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry, 74(6), 597–603.
Liu, Y.-C., Chen, V. C.-H., Yang, Y.-H., Chen, Y.-L., & Gossop, M. (2021). Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. Epidemiology and Psychiatric Sciences, 30, Article e14.
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012). Medication for attention deficit–hyperactivity disorder and criminality. New England Journal of Medicine, 367(21), 2006–2014.
Dalsgaard, S., Nielsen, H. S., & Simonsen, M. (2014). Consequences of ADHD medication use for children’s outcomes. Journal of Health Economics, 37, 137–151.
Taipale, H., Bergström, J., Gèmes, K., Tanskanen, A., Ekselius, L., Mittendorfer-Rutz, E., & Helgesson, M. (2024). Attention-deficit/hyperactivity disorder medications and work disability and mental health outcomes. JAMA Network Open, 7(3), Article e242859.
Sun, S., Kuja-Halkola, R., Faraone, S. V., D’Onofrio, B. M., Dalsgaard, S., Chang, Z., & Larsson, H. (2019). Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit/hyperactivity disorder. JAMA Psychiatry, 76(11), 1141–1149.
Thapar, A. K., Collishaw, S., Davey Smith, G., Stergiakouli, E., & Thapar, A. (2026). Association between childhood ADHD problems and premature mortality: Identifying modifiable cardiovascular mechanisms in a UK population cohort. Frontiers in Psychiatry, 17, Article 1764335.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Lena Głuszkiewicz, Sara Elżbieta Czubak, Michalina Weronika Nieścioruk, Dominika Julia Kozdroń, Jan Szafranek, Julia Beata Woźniak, Jakub Marcel Korowicki
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
